Publications by authors named "C Nabhan"
Article Synopsis
- This study focused on the diverse types of FOXA1 genetic alterations found in prostate cancer and their implications for clinical management.
- Researchers classified FOXA1 mutations into four distinct classes, each with specific characteristics and prognostic significance based on survival outcomes.
- Results indicated that certain FOXA1 alterations, particularly class 1A, were linked to improved survival rates, while other classes, especially class 2 and amplified versions, were associated with poorer outcomes and higher risks in treatment response.
Immunotherapy has changed the treatment paradigm for many types of cancer, but immune checkpoint inhibitors (ICIs) have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment (TME) and is associated with poor response to ICIs. The primary source of inflammatory cytokine production is the inflammasome.
View Article and Find Full Text PDFArticle Synopsis
- - The study analyzed genomic and transcriptomic data from 138 germ cell tumors to find out why some tumors resist treatment with cisplatin, a common chemotherapy drug.
- - They focused on specific genetic mutations (like KRAS, TP53, and KIT) and patterns in gene copies that might contribute to this resistance, observing that certain mutations were more common in primary tumors compared to metastatic ones.
- - The research found that tumors with platinum-resistant alterations had lower transcriptomic scores linked to sensitivity to cisplatin, indicating a possible connection between these genetic changes and treatment resistance.
Introduction: In May 2022, the Centers for Disease Control and Prevention disseminated an alert advising that "a few" persons with Nirmatrelvir/ritonavir (NM/R)-associated rebound of COVID-19 infection had been identified. Three case reports appearing as pre-print postings described the first cases. Analyses in March 2023 by NM/R's manufacturer and the Food and Drug Administration (FDA) reported no association between NM/R and COVID-19 rebound in a large phase 3 randomized clinical trial.
View Article and Find Full Text PDFArticle Synopsis
- Metastases, which are the spread of cancer cells to different organs, play a crucial role in the severity of renal cell carcinoma (RCC), with common sites being the lungs, bones, liver, and lymph nodes.
- This study analyzed 657 tumor samples from both primary renal tumors and various metastatic sites to identify genomic and transcriptomic differences.
- The findings reveal significant variations in tumor characteristics and the tumor microenvironment across different metastatic locations, highlighting the importance of these factors in creating targeted cancer treatments.